AMYLOID BETA PROTEIN

Clinical trials for AMYLOID BETA PROTEIN explained in plain language.

Never miss a new study

Get alerted when new AMYLOID BETA PROTEIN trials appear

Sign up with your email to follow new studies for AMYLOID BETA PROTEIN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug trial targets Alzheimer's risk in down syndrome

Disease control Not yet recruiting

This study is testing whether the drug donanemab can reduce the buildup of a harmful protein called amyloid in the brains of adults with Down syndrome. About 60 participants, aged 35-50, will receive monthly infusions of either donanemab or a placebo for one year, followed by an …

Matched conditions: AMYLOID BETA PROTEIN

Phase: PHASE4 • Sponsor: Michael Rafii, MD, PhD • Aim: Disease control

Last updated Mar 25, 2026 14:07 UTC

AMYLOID BETA PROTEIN

Get alerted when new AMYLOID BETA PROTEIN trials appear

New drug trial targets Alzheimer's risk in down syndrome